- Home
- GNPX vs MITQ Comparison
GNPX vs MITQ Comparison
Compare GNPX & MITQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- MITQ
- Stock Information
- Founded
- GNPX 2009
- MITQ N/A
- Country
- GNPX United States
- MITQ United States
- Employees
- GNPX N/A
- MITQ N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- MITQ Telecommunications Equipment
- Sector
- GNPX Health Care
- MITQ Telecommunications
- Exchange
- GNPX Nasdaq
- MITQ Nasdaq
- Market Cap
- GNPX 6.6M
- MITQ 5.5M
- IPO Year
- GNPX 2018
- MITQ 2021
- Fundamental
- Price
- GNPX $0.28
- MITQ $0.72
- Analyst Decision
- GNPX
- MITQ
- Analyst Count
- GNPX 0
- MITQ 0
- Target Price
- GNPX N/A
- MITQ N/A
- AVG Volume (30 Days)
- GNPX 3.4M
- MITQ 9.8M
- Earning Date
- GNPX 08-08-2025
- MITQ 05-15-2025
- Dividend Yield
- GNPX N/A
- MITQ N/A
- EPS Growth
- GNPX N/A
- MITQ N/A
- EPS
- GNPX N/A
- MITQ N/A
- Revenue
- GNPX N/A
- MITQ $18,613,000.00
- Revenue This Year
- GNPX N/A
- MITQ N/A
- Revenue Next Year
- GNPX N/A
- MITQ N/A
- P/E Ratio
- GNPX N/A
- MITQ N/A
- Revenue Growth
- GNPX N/A
- MITQ N/A
- 52 Week Low
- GNPX $0.20
- MITQ $0.50
- 52 Week High
- GNPX $3.97
- MITQ $1.55
- Technical
- Relative Strength Index (RSI)
- GNPX 55.29
- MITQ 61.52
- Support Level
- GNPX $0.25
- MITQ $0.63
- Resistance Level
- GNPX $0.27
- MITQ $0.75
- Average True Range (ATR)
- GNPX 0.03
- MITQ 0.06
- MACD
- GNPX 0.00
- MITQ 0.01
- Stochastic Oscillator
- GNPX 90.71
- MITQ 74.86
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.